Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jürgen E Gschwend

Showing results (1-10 of 204) with videos related to

Pageof 21
Sort By:
Onkologie|February 19, 2010
[Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma]Jürgen E Gschwend
Current Opinion in Urology|October 16, 2003
Bladder substitutionJürgen E Gschwend
European Urology|December 4, 2003
Malignant non-urothelial neoplasms of the urinary bladder: a reviewPhilipp Dahm, Jürgen E Gschwend
European Urology Focus|August 24, 2019
Extended Lymph Node Dissection for Bladder Cancer: Do Clinical Trials Rule Out a Benefit?Matthias M Heck, Jürgen E Gschwend
Current Opinion in Urology|October 14, 2017
Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastasesTobias Maurer, Jürgen E Gschwend, Matthias Eiber
Urologie (Heidelberg, Germany)|February 8, 2024
[Salvage lymphadenectomy for recurrent prostate cancer]Thomas Horn, Flemming Lischewski, Jürgen E Gschwend
Der Urologe. Ausg. A|April 4, 2022
[Aftercare and adjuvant therapy for advanced renal cell carcinoma]Lukas Lunger, Thomas Amiel, Jürgen E Gschwend
European Urology|June 21, 2002
Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomyJürgen E Gschwend, Philipp Dahm, William R Fair
Urologie (Heidelberg, Germany)|June 15, 2023
[New tracers and combinations in radioligand therapy for prostate cancer]Robert Tauber, Lukas Lunger, Matthias Eiber, et al.
Nature Reviews. Urology|February 24, 2016
Current use of PSMA-PET in prostate cancer managementTobias Maurer, Matthias Eiber, Markus Schwaiger, et al.
Pageof 21

Showing results (1-10 of 204) with videos related to

Sort By:
Pageof 21
Onkologie|February 19, 2010
[Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma]Jürgen E Gschwend
Current Opinion in Urology|October 16, 2003
Bladder substitutionJürgen E Gschwend
European Urology|December 4, 2003
Malignant non-urothelial neoplasms of the urinary bladder: a reviewPhilipp Dahm, Jürgen E Gschwend
European Urology Focus|August 24, 2019
Extended Lymph Node Dissection for Bladder Cancer: Do Clinical Trials Rule Out a Benefit?Matthias M Heck, Jürgen E Gschwend
Current Opinion in Urology|October 14, 2017
Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastasesTobias Maurer, Jürgen E Gschwend, Matthias Eiber
Urologie (Heidelberg, Germany)|February 8, 2024
[Salvage lymphadenectomy for recurrent prostate cancer]Thomas Horn, Flemming Lischewski, Jürgen E Gschwend
Der Urologe. Ausg. A|April 4, 2022
[Aftercare and adjuvant therapy for advanced renal cell carcinoma]Lukas Lunger, Thomas Amiel, Jürgen E Gschwend
European Urology|June 21, 2002
Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomyJürgen E Gschwend, Philipp Dahm, William R Fair
Urologie (Heidelberg, Germany)|June 15, 2023
[New tracers and combinations in radioligand therapy for prostate cancer]Robert Tauber, Lukas Lunger, Matthias Eiber, et al.
Nature Reviews. Urology|February 24, 2016
Current use of PSMA-PET in prostate cancer managementTobias Maurer, Matthias Eiber, Markus Schwaiger, et al.
Pageof 21